UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,822 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 11.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 212,887 shares of the company's stock after purchasing an additional 21,822 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.17% of Apellis Pharmaceuticals worth $6,793,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC lifted its holdings in shares of Apellis Pharmaceuticals by 18.0% during the 3rd quarter. Barclays PLC now owns 255,897 shares of the company's stock worth $7,381,000 after acquiring an additional 39,019 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Apellis Pharmaceuticals by 12.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,376 shares of the company's stock worth $842,000 after buying an additional 2,956 shares during the period. Jennison Associates LLC boosted its position in Apellis Pharmaceuticals by 51.6% in the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company's stock valued at $88,084,000 after buying an additional 939,289 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at about $445,000. Finally, Savant Capital LLC increased its position in shares of Apellis Pharmaceuticals by 42.5% during the fourth quarter. Savant Capital LLC now owns 31,525 shares of the company's stock worth $1,006,000 after acquiring an additional 9,407 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

Insider Activity

In related news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 6.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Cantor Fitzgerald started coverage on Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $44.00 target price for the company. JPMorgan Chase & Co. lifted their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. The Goldman Sachs Group reduced their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Finally, Scotiabank decreased their target price on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a report on Thursday, May 8th. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.05.

Apellis Pharmaceuticals Price Performance

Shares of APLS traded down $0.32 during mid-day trading on Tuesday, reaching $18.82. The company had a trading volume of 1,896,142 shares, compared to its average volume of 2,300,101. The company's 50 day simple moving average is $18.82 and its 200 day simple moving average is $25.85. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -9.27 and a beta of 0.73. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.10 and a 1-year high of $43.76. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm's revenue was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.54) earnings per share. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).